Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 12, 2016 7:49 PM ET

Pharmaceuticals

Company Overview of Nektar Therapeutics

Executive Profile

Susan S. Wang

Independent Director and Chairman of Audit Committee, Nektar Therapeutics
AgeTotal Calculated CompensationThis person is connected to 3 Board Members in 3 different organizations across 10 different industries.

See Board Relationships
51$349,213

Background

Ms. Susan S. Wang served as the Chief Financial Officer, Executive Vice President of Corporate Development and Corporate Secretary at Solectron Corporation. Ms. Wang retired from Solectron in June 2002 and has held several key positions during her 18 years. She is a Financial Expert. Before joining Solectron in 1984, she held financial and managerial positions with Xerox Corporation, Westvaco Corporation, Price Waterhouse LLP and Price Waterhouse & Co. She has over 25 ...

Corporate Headquarters

455 Mission Bay Boulevard South
San Francisco, California 94158

United States

Phone: 415-482-5300
Fax: 415-339-5300

Board Members Memberships

2003-Present
Independent Director and Chairman of Audit Committee
2013-Present
Independent Director, Chairman of Audit & Compliance Committee, Member of Member Agreement Review Committee and Member of Conflict Advisory Committee
2015-Present
Director and Member of Audit Committee

Education

BBA 1972
The University of Texas System
MBA 1981
University of Connecticut

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

Total Annual Cash Compensation$82,250
Total Calculated Compensation$349,213
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President and Director
Innoviva, Inc.
$557.2K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
Peter William Grant Chief Executive Officer and Executive Director
Skyepharma PLC
$615.0K
Peter S. Greenleaf Chairman and Chief Executive Officer
Sucampo Pharmaceuticals, Inc.
$440.2K
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director, Member of Strategic Operations Committee and Member of Pricing Committee
Emergent BioSolutions, Inc.
$1.2M
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Nektar Therapeutics, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.